CTMX CytomX Therapeutics Inc.

7.27
-0.23  -3%
Previous Close 7.5
Open 7.33
Price To Book 4.02
Market Cap 330,306,372
Shares 45,434,164
Volume 86,222
Short Ratio
Av. Daily Volume 464,682
Stock charts supplied by TradingView

NewsSee all news

  1. CytomX Therapeutics Announces New Employment Inducement Grants

    SOUTH SAN FRANCISCO, Calif., Jan. 17, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody

  2. CytomX Therapeutics Provides Updates on Lead Clinical Programs and 2020 Portfolio Outlook

     - Wholly-Owned anti-PD-L1 and anti-CD166 Programs Entering Phase 2 Studies – - Partnered Clinical Programs Advancing - - Multiple Updates Anticipated Across Portfolio in 2020 - SOUTH SAN FRANCISCO, Calif.,

  3. CytomX Therapeutics Announces New Employment Inducement Grants

    SOUTH SAN FRANCISCO, Calif., Dec. 17, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody

  4. CytomX Therapeutics Announces New Employment Inducement Grants

    SOUTH SAN FRANCISCO, Calif., Dec. 06, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody

  5. CytomX Therapeutics to Present at Upcoming Healthcare Conferences

    SOUTH SAN FRANCISCO, Calif., Nov. 11, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 final data from monotherapy expansion trials and initial combo data in melanoma due 2020.
PROCLAIM-CX-072-002
Solid tumors
Phase 1/2 initial data to be presented 2020.
BMS-986249 and nivolumab
Solid Tumors or Lymphomas
Phase 1 updated dose escalation data due 2020.
CX-2009 - PROCLAIM
Solid tumors
Phase 1 initial dose escalation data due 2020.
PROCLAIM-CX-2029
Solid tumors / diffuse large B-cell lymphoma (DLBCL)

Latest News

  1. CytomX Therapeutics Announces New Employment Inducement Grants

    SOUTH SAN FRANCISCO, Calif., Jan. 17, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody

  2. CytomX Therapeutics Provides Updates on Lead Clinical Programs and 2020 Portfolio Outlook

     - Wholly-Owned anti-PD-L1 and anti-CD166 Programs Entering Phase 2 Studies – - Partnered Clinical Programs Advancing - - Multiple Updates Anticipated Across Portfolio in 2020 - SOUTH SAN FRANCISCO, Calif.,

  3. CytomX Therapeutics Announces New Employment Inducement Grants

    SOUTH SAN FRANCISCO, Calif., Dec. 17, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody

  4. CytomX Therapeutics Announces New Employment Inducement Grants

    SOUTH SAN FRANCISCO, Calif., Dec. 06, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody

  5. CytomX Therapeutics to Present at Upcoming Healthcare Conferences

    SOUTH SAN FRANCISCO, Calif., Nov. 11, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody

  6. CytomX Therapeutics Announces Third Quarter 2019 Financial Results and Provides Business Update

    SOUTH SAN FRANCISCO, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody

  7. CytomX Therapeutics Announces Initiation of Phase 2 Clinical Trial Evaluating the Anti-PD-L1 Probody CX-072 in Combination with YERVOY® in Patients with Relapsed or Refractory Melanoma

    SOUTH SAN FRANCISCO, Calif., Oct. 29, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody

  8. CytomX Therapeutics Announces Appointment of Amy C. Peterson, M.D. as Chief Development Officer

    -Industry Veteran Joins to Advance Maturing Platform and Pipeline to Next Phase of Development- -Product Development Team Further Strengthened with Appointment of Glenn Michelson, M.D., as Vice President, Clinical

  9. CytomX Therapeutics to Present at Upcoming Healthcare Conferences

    SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody